{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:23:14Z","timestamp":1783016594823,"version":"3.54.6"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102981"],"award-info":[{"award-number":["82102981"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Startup Fund for Scientific Research of Fujian Medical University","award":["2020QH1136"],"award-info":[{"award-number":["2020QH1136"]}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2022J05073"],"award-info":[{"award-number":["2022J05073"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2021J01384"],"award-info":[{"award-number":["2021J01384"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Joint Funds for the Innovation of Science and Technology, Fujian Province","award":["2023Y9352"],"award-info":[{"award-number":["2023Y9352"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-025-04416-0","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T14:15:04Z","timestamp":1761315304000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of neoadjuvant camrelizumab and apatinib combined with chemotherapy in stage IIIA (N2) NSCLC: a multi-center, single-arm, phase II trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Lilan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liren","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongzhi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenshu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"issue":"9","key":"4416_CR1","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.annonc.2022.06.013","volume":"33","author":"F Cortiula","year":"2022","unstructured":"Cortiula F, Reymen B, Peters S, Van Mol P, Wauters E, Vansteenkiste J, et al. Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches. Ann Oncol. 2022;33(9):893\u2013908.","journal-title":"Ann Oncol"},{"issue":"12","key":"4416_CR2","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.21.02528","volume":"40","author":"ME Daly","year":"2022","unstructured":"Daly ME, Singh N, Ismaila N, Antonoff MB, Arenberg DA, Bradley J, et al. Management of stage III non-small-cell lung cancer: ASCO guideline. J Clin Oncol. 2022;40(12):1356\u201384.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4416_CR3","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1183\/13993003.01490-2015","volume":"47","author":"D Subotic","year":"2016","unstructured":"Subotic D, Van Schil P, Grigoriu B. Optimising treatment for post-operative lung cancer recurrence. Eur Respir J. 2016;47(2):374\u20138.","journal-title":"Eur Respir J"},{"issue":"4","key":"4416_CR4","first-page":"242","volume":"3","author":"H Uramoto","year":"2014","unstructured":"Uramoto H, Tanaka F. Recurrence after surgery in patients with NSCLC. Transl Lung Cancer Res. 2014;3(4):242\u20139.","journal-title":"Transl Lung Cancer Res"},{"key":"4416_CR5","doi-asserted-by":"crossref","unstructured":"Group NM-aC: Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet 2014, 383(9928):1561\u20131571.","DOI":"10.1016\/S0140-6736(13)62159-5"},{"issue":"5","key":"4416_CR6","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","volume":"3","author":"LA Emens","year":"2015","unstructured":"Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015;3(5):436\u201343.","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"4416_CR7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S2213-2600(20)30365-9","volume":"9","author":"C Zhou","year":"2021","unstructured":"Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med. 2021;9(3):305\u201314.","journal-title":"Lancet Respir Med"},{"issue":"4","key":"4416_CR8","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","volume":"17","author":"S Ren","year":"2022","unstructured":"Ren S, Chen J, Xu X, Jiang T, Cheng Y, Chen G, et al. Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (camel-sq): a phase 3 trial. J Thorac Oncol. 2022;17(4):544\u201357.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"4416_CR9","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1016\/S1470-2045(21)00460-5","volume":"22","author":"H Cheng","year":"2021","unstructured":"Cheng H, Zong L, Kong Y, Wang X, Gu Y, Cang W, et al. Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial. Lancet Oncol. 2021;22(11):1609\u201317.","journal-title":"Lancet Oncol"},{"issue":"34","key":"4416_CR10","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1200\/JCO.20.01920","volume":"38","author":"C Lan","year":"2020","unstructured":"Lan C, Shen J, Wang Y, Li J, Liu Z, He M, et al. Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): a multicenter, open-label, single-arm, phase II trial. J Clin Oncol. 2020;38(34):4095\u2013106.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4416_CR11","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1158\/1078-0432.CCR-18-2484","volume":"25","author":"J Xu","year":"2019","unstructured":"Xu J, Zhang Y, Jia R, Yue C, Chang L, Liu R, et al. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study. Clin Cancer Res. 2019;25(2):515\u201323.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"4416_CR12","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380(12):1116\u201327.","journal-title":"N Engl J Med"},{"issue":"12","key":"4416_CR13","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103\u201315.","journal-title":"N Engl J Med"},{"issue":"2","key":"4416_CR14","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","volume":"20","author":"AX Zhu","year":"2019","unstructured":"Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282\u201396.","journal-title":"Lancet Oncol"},{"issue":"20","key":"4416_CR15","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"5","key":"4416_CR16","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","volume":"15","author":"KA Khan","year":"2018","unstructured":"Khan KA, Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol. 2018;15(5):310\u201324.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"4416_CR17","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1158\/2159-8290.CD-20-1209","volume":"11","author":"TA Yap","year":"2021","unstructured":"Yap TA, Parkes EE, Peng W, Moyers JT, Curran MA, Tawbi HA. Development of immunotherapy combination strategies in cancer. Cancer Discov. 2021;11(6):1368\u201397.","journal-title":"Cancer Discov"},{"issue":"8","key":"4416_CR18","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-021-00496-y","volume":"18","author":"ZR Huinen","year":"2021","unstructured":"Huinen ZR, Huijbers EJM, van Beijnum JR, Nowak-Sliwinska P, Griffioen AW. Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nat Rev Clin Oncol. 2021;18(8):527\u201340.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"4416_CR19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325\u201340.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"4416_CR20","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.jtho.2023.02.019","volume":"18","author":"J Zhao","year":"2023","unstructured":"Zhao J, Zhao L, Guo W, Wang S, Tao X, Li L, et al. Efficacy, safety, and biomarker analysis of neoadjuvant camrelizumab and apatinib in patients with resectable NSCLC: a phase 2 clinical trial. J Thorac Oncol. 2023;18(6):780\u201391.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"4416_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01861-w","volume":"9","author":"H Xia","year":"2024","unstructured":"Xia H, Zhang H, Ruan Z, Zhang H, Sun L, Chen H, et al. Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II-III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study. Signal Transduct Target Ther. 2024;9(1):145.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"4416_CR22","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jtho.2020.01.005","volume":"15","author":"WD Travis","year":"2020","unstructured":"Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, et al. IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy. J Thorac Oncol. 2020;15(5):709\u201340.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"4416_CR23","doi-asserted-by":"publisher","first-page":"94","DOI":"10.21873\/cgp.20306","volume":"19","author":"A Nastase","year":"2022","unstructured":"Nastase A, Dima SO, Lupo A, Laszlo V, Tagett R, Draghici S, et al. Molecular markers for long-term survival in stage IIIA (N2) NSCLC patients. Cancer Genomics Proteomics. 2022;19(1):94\u2013104.","journal-title":"Cancer Genomics Proteomics"},{"issue":"1","key":"4416_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-025-04250-4","volume":"23","author":"S Ji","year":"2025","unstructured":"Ji S, Sheng Z, Bian D, Bao M, Jin K, Zhang W, et al. Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA-IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial. BMC Med. 2025;23(1):429.","journal-title":"BMC Med"},{"issue":"21","key":"4416_CR25","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378(21):1976\u201386.","journal-title":"N Engl J Med"},{"issue":"10","key":"4416_CR26","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1038\/s41591-022-01962-5","volume":"28","author":"JE Chaft","year":"2022","unstructured":"Chaft JE, Oezkan F, Kris MG, Bunn PA, Wistuba II, Kwiatkowski DJ, et al. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. Nat Med. 2022;28(10):2155\u201361.","journal-title":"Nat Med"},{"issue":"11","key":"4416_CR27","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","volume":"21","author":"M Provencio","year":"2020","unstructured":"Provencio M, Nadal E, Insa A, Garcia-Campelo MR, Casal-Rubio J, Domine M, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(11):1413\u201322.","journal-title":"Lancet Oncol"},{"issue":"22","key":"4416_CR28","doi-asserted-by":"publisher","first-page":"8406","DOI":"10.1002\/cam4.3456","volume":"9","author":"A Tfayli","year":"2020","unstructured":"Tfayli A, Al Assaad M, Fakhri G, Akel R, Atwi H, Ghanem H, et al. Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer. Cancer Med. 2020;9(22):8406\u201311.","journal-title":"Cancer Med"},{"issue":"10","key":"4416_CR29","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1001\/jamaoncol.2023.2751","volume":"9","author":"J Lei","year":"2023","unstructured":"Lei J, Zhao J, Gong L, Ni Y, Zhou Y, Tian F, et al. Neoadjuvant camrelizumab plus platinum-based chemotherapy vs chemotherapy alone for Chinese patients with resectable stage IIIA or IIIB (T3N2) non-small cell lung cancer: the TD-FOREKNOW randomized clinical trial. JAMA Oncol. 2023;9(10):1348\u201355.","journal-title":"JAMA Oncol"},{"issue":"2","key":"4416_CR30","doi-asserted-by":"publisher","first-page":"398","DOI":"10.21037\/tlcr-23-144","volume":"13","author":"Y Bai","year":"2024","unstructured":"Bai Y, Yang W, Kasmann L, Sorich MJ, Tao H, Hu Y. Immunotherapy for advanced non-small cell lung cancer with negative programmed death-ligand 1 expression: a literature review. Transl Lung Cancer Res. 2024;13(2):398\u2013422.","journal-title":"Transl Lung Cancer Res"},{"key":"4416_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108621","volume":"205","author":"M Gemelli","year":"2025","unstructured":"Gemelli M, Cortinovis D, Carola G, Moretti L, Piazza F, Calza S, et al. Efficacy of immune checkpoint inhibitors (ICIs) in PD-L1 negative non-small cell lung cancer (NSCLC) - a meta-analysis based on reconstructed individual participant data. Lung Cancer. 2025;205:108621.","journal-title":"Lung Cancer"},{"issue":"1","key":"4416_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01355-1","volume":"8","author":"M Shao","year":"2023","unstructured":"Shao M, Yao J, Wang Y, Zhao L, Li B, Li L, et al. Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoscore trial. Signal Transduct Target Ther. 2023;8(1):146.","journal-title":"Signal Transduct Target Ther"},{"issue":"21","key":"4416_CR33","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973\u201385.","journal-title":"N Engl J Med"},{"issue":"26","key":"4416_CR34","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.21.00276","volume":"39","author":"SI Rothschild","year":"2021","unstructured":"Rothschild SI, Zippelius A, Eboulet EI, Savic Prince S, Betticher D, Bettini A, et al. SAKK 16\/14: durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small-cell lung cancer-a multicenter single-arm phase II trial. J Clin Oncol. 2021;39(26):2872\u201380.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4416_CR35","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S1470-2045(20)30140-6","volume":"21","author":"CA Shu","year":"2020","unstructured":"Shu CA, Gainor JF, Awad MM, Chiuzan C, Grigg CM, Pabani A, et al. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(6):786\u201395.","journal-title":"Lancet Oncol"},{"key":"4416_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102422","volume":"68","author":"C Sun","year":"2024","unstructured":"Sun C, Wang X, Xu Y, Shao G, Chen X, Liu Y, et al. Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA\/IIIB non-small cell lung cancer: neo-pre-IC, a single-arm phase 2 trial. EClinicalMedicine. 2024;68:102422.","journal-title":"EClinicalMedicine"},{"issue":"6","key":"4416_CR37","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.jtho.2023.01.083","volume":"18","author":"X Hou","year":"2023","unstructured":"Hou X, Zhou C, Wu G, Lin W, Xie Z, Zhang H, et al. Efficacy, safety, and health-related quality of life with camrelizumab plus pemetrexed and carboplatin as first-line treatment for advanced nonsquamous NSCLC with brain metastases (CAP-BRAIN): a multicenter, open-label, single-arm, phase 2 study. J Thorac Oncol. 2023;18(6):769\u201379.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"4416_CR38","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jtho.2022.12.017","volume":"18","author":"C Zhou","year":"2023","unstructured":"Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, et al. Camrelizumab plus carboplatin and pemetrexed as first-line treatment for advanced nonsquamous NSCLC: extended follow-up of CameL phase 3 trial. J Thorac Oncol. 2023;18(5):628\u201339.","journal-title":"J Thorac Oncol"},{"key":"4416_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102403","volume":"67","author":"X Pu","year":"2024","unstructured":"Pu X, Lin G, Xiao M, Lin J, Wang Q, Kong Y, et al. Camrelizumab combined with apatinib and nanoparticle albumin-bound paclitaxel in lung adenocarcinoma (CAPAP-lung): a single-arm phase II study. eClinicalMedicine. 2024;67:102403.","journal-title":"eClinicalMedicine"},{"issue":"5","key":"4416_CR40","volume":"3","author":"S Ren","year":"2022","unstructured":"Ren S, He J, Fang Y, Chen G, Ma Z, Chen J, et al. Camrelizumab plus apatinib in treatment-naive patients with advanced nonsquamous NSCLC: a multicenter, open-label, single-arm, phase 2 trial. JTO Clin Res Rep. 2022;3(5):100312.","journal-title":"JTO Clin Res Rep"},{"issue":"5","key":"4416_CR41","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1158\/1078-0432.CCR-20-3136","volume":"27","author":"C Zhou","year":"2021","unstructured":"Zhou C, Wang Y, Zhao J, Chen G, Liu Z, Gu K, et al. Efficacy and biomarker analysis of camrelizumab in combination with apatinib in patients with advanced nonsquamous NSCLC previously treated with chemotherapy. Clin Cancer Res. 2021;27(5):1296\u2013304.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4416_CR42","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","volume":"27","author":"J Xu","year":"2021","unstructured":"Xu J, Shen J, Gu S, Zhang Y, Wu L, Wu J, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial. Clin Cancer Res. 2021;27(4):1003\u201311.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4416_CR43","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.4103\/jcrt.JCRT_997_19","volume":"15","author":"W Li","year":"2019","unstructured":"Li W, Wei Z, Yang X, Huang G, Han X, Ni Y, et al. Salvage therapy of reactive capillary hemangiomas: Apatinib alleviates the unique adverse events induced by camrelizumab in non-small cell lung cancer. J Cancer Res Ther. 2019;15(7):1624\u20138.","journal-title":"J Cancer Res Ther"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04416-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04416-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04416-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T15:03:10Z","timestamp":1761318190000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-04416-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4416"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04416-0","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"31 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of Fuzhou University Affiliated Provincial Hospital (2020\u2013010-03), Fuzhou Pulmonary Hospital of Fujian (2021\u2013020-01), Zhangzhou Affiliated Hospital of Fujian Medical University (2021\u2013035-03), and The First Affiliated Hospital of Xiamen University (2022\u2013007). The study was conducted following the Declaration of Helsinki, Good Clinical Practice, and local laws and regulatory requirements. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"585"}}